NCT02983968

Brief Summary

Hepatocellular carcinoma (HCC) has become the second most common cause of cancer death in the world, estimated responsible for nearly 745,000 deaths in 2012 (9.1% of all cancer deaths).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
890

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 30, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 6, 2016

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2018

Completed
Last Updated

August 6, 2018

Status Verified

August 1, 2018

Enrollment Period

2 years

First QC Date

November 30, 2016

Last Update Submit

August 3, 2018

Conditions

Cirrhosis

Keywords

OncologyHepatologyPublic HealthLiver

Outcome Measures

Primary Outcomes (1)

  • Rate of deviation from the guidelines

    01/01/2007 - 01/01/2018

Secondary Outcomes (1)

  • Factors associated with deviation from the guidelines

    01/01/2007 - 01/01/2018

Interventions

Description of the cirrhosis managementOTHER

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Cirrhotic patients aged between 18 and 75 years

You may qualify if:

  • \- Cirrhotic patients aged between 18 and 75 years.
  • (A cirrhotic patient will be defined as a presenting a first occurrence of a codes used in hospitalisation for cirrhosis or as a motive for granting an ALD 6 (cirrhosis motivated) financial support )

You may not qualify if:

  • \- None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens

Amiens, 80084, France

RECRUITING

MeSH Terms

Conditions

FibrosisNeoplasms

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Olivier GANRY, MD, PhD

    CHU Amiens

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Olivier GANRY, MD, PhD

CONTACT

+33 3 66 81 93ganry.olivier@chu-amiens.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 30, 2016

First Posted

December 6, 2016

Study Start

September 1, 2016

Primary Completion

September 1, 2018

Study Completion

October 1, 2018

Last Updated

August 6, 2018

Record last verified: 2018-08

Locations

FR(1)